Related Experiment Video

Updated: Jul 13, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

27.0K

Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany

Alexander Kuhlmann1, J-Matthias Graf von der Schulenburg2

  • 1Center for Health Economics Research Hannover (CHERH), Leibniz Universität Hannover, Otto-Brenner-Straße 1, 30159, Hanover, Germany. ak@ivbl.uni-hannover.de.

The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|February 25, 2016
PubMed

Insights

Pneumococcal conjugate vaccine 13 (PCV13) is a cost-effective infant vaccination strategy compared to PCV10 in Germany. This holds true if PCV13 provides significant indirect health benefits, improving overall public health outcomes.

Area of Science:

  • Public Health
  • Vaccinology
  • Health Economics

Background:

  • Germany approved higher-valent pneumococcal conjugate vaccines in 2009.
  • Pneumococcal disease prevention in infants is a key public health concern.

Purpose of the Study:

  • To evaluate the cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) versus 10-valent pneumococcal conjugate vaccine (PCV10) for universal infant vaccination in Germany.
  • To compare the impact of PCV13 and PCV10 on invasive pneumococcal disease, pneumonia, and acute otitis media.

Main Methods:

  • A population-based Markov model simulated disease impact over 50 years.
  • Included infant vaccination, herd effects, and replacement disease.
  • Utilized German epidemiological data and sensitivity analyses for parameter uncertainty.

Main Results:

  • PCV13 vaccination yielded an Incremental Cost-Effectiveness Ratio (ICER) of €9826/QALY (societal) and €3368/QALY (statutory health insurance).
  • Results were sensitive to indirect vaccine effects.
  • PCV13 demonstrated favorable cost-effectiveness from both societal and health insurance perspectives.

Conclusions:

  • Universal infant vaccination with PCV13 is likely cost-effective compared to PCV10 in Germany.
  • The cost-effectiveness is contingent on significant net indirect effects of PCV13.
  • PCV13 represents a potentially valuable public health intervention for pneumococcal disease prevention.
Abstract

Keywords:
Cost-effectivenessCostsEconomic evaluationHerd protectionPneumococcal conjugate vaccineVaccination

More Related Videos

Expansion of Embryonic and Adult Neural Stem Cells by In Utero Electroporation or Viral Stereotaxic Injection19:45

Expansion of Embryonic and Adult Neural Stem Cells by In Utero Electroporation or Viral Stereotaxic Injection

Published on: October 6, 2012

17.7K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...